Investor Presentation October 2011 OTCBB: BLFS

OCTOBER 2011 INVESTOR PRESENTATION 2 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 including, but not limited to, statements about BioLife Solutions, Inc. (the “Company”) and its future operating results, strategies, and product development plans. These forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties. Actual results could differ materially from the results expressed or implied in these forward-looking statements. Factors that may cause or contribute to such differences are more fully discussed, as are other factors, in Part I, Item1A. “Risk Factors” of the Company’s Form 10-K for the fiscal year ended December 31, 2010, which was filed with the SEC on March 28, 2011. In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as of any subsequent date. While the Company may elect to update forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so except as may be legally necessary, even if the Company’s estimates should change.

OCTOBER 2011 INVESTOR PRESENTATION 3 Leading Innovator Serving $500M Market NEXT-GENERATION PRODUCTS SCALABLE PRODUCTION FACILITY LARGE, GROWING CUSTOMER BASE Proprietary, best-in-class biopreserveration media products for cells, tissues and organs $25MM annual revenue capacity in a scalable GMP facility 300+ customers and key distributors in strategic market segments: Regenerative Medicine Biobanking Drug Discovery

OCTOBER 2011 INVESTOR PRESENTATION 4 Products and Services cGMP, Serum-free, protein-free biopreservation media products for cells, tissues, and organs HypoThermosol® CryoStor® BloodStor® Hypothermic storage & shipping media Cryopreservation freeze media Cord blood stem cell freeze media

Target Markets OCTOBER 2011 INVESTOR PRESENTATION 5 Pharmaceutical companies, cell suppliers, toxicity testing labs

Regenerative Medicine Opportunity Use of traditional, archaic “home brew” cocktail results in yield loss and limited shelf life of precious cells intended for clinical applications. Developers face increasing quality and regulatory pressure to switch to pre-formulated, engineered media and reagents. Fragile, live cells from source materials such as blood, tissue, and organs are enabling the development of biologic-based therapies and treatments for the leading causes of death and disability. These must be transported from the processing lab to the bedside in a refrigerated or frozen state to preserve viability, quality, and potency. This is Biopreservation! OCTOBER 2011 INVESTOR PRESENTATION 6

5- CONFIDENTIAL AND PROPRIETARY OCTOBER 2011 INVESTOR PRESENTATION Pre-formulated  cGMP  Serum-free  Protein-free BioLife Products Meet The Opportunity Enable 2x to 3x longer shelf-life of cell and tissue-based clinical therapies – several days! Increase the yield and viability of cells in the clinical dose 7

OCTOBER 2011 INVESTOR PRESENTATION 8 CryoStor® & HypoThermosol® In Customer Clinical Trials Any successful commercial application could result in $1-2M revenue per year

Rapidly Expanding Market OCTOBER 2011 INVESTOR PRESENTATION 9 $32B $7B $500M $150M Source: VisionGain Source: Management estimates, Axis Research Mind Regenerative Medicine Market Growth (Billions) Demand for Biopreservation Media (Millions)

Why Our Products Are In High Demand Outperform all other biopreservation media Highest quality - GMP Customer service BioLife Preserved Cells Competitive Products OCTOBER 2011 INVESTOR PRESENTATION 10

Traditional, culture media-based formulas Separate components sourced from multiple vendors Mixing required for each daily/weekly batch Components typically not USP quality Limited release criteria and not for every batch Non-GMP process Limited biopreservation efficacy OCTOBER 2011 INVESTOR PRESENTATION 11 Competition Home-Brew Biopreservation Media

OCTOBER 2011 INVESTOR PRESENTATION 12 How Our Products Are Different BioLife Biopreservation Media Advantages Proprietary formula, optimized to protect cells from low temperature stress Mitigates apoptosis & necrosis Free radical scavengers Energy substrates pH buffers Pre-Formulated – no mixing required cGMP manufactured USP or highest quality components USP sterility tested USP endotoxin tested Bioassay tested FDA Master File

Diverse Customer Base OCTOBER 2011 INVESTOR PRESENTATION 13 Estimated 2010 Segment Revenues Regenerative Medicine Drug Discovery BioBanking Distributor Contract Mfg

OCTOBER 2011 INVESTOR PRESENTATION 14 Industry Leading Customers

15 7 issued patents 5 submitted applications Over 200 third-party issued and pending patents citing BioLife products OCTOBER 2011 INVESTOR PRESENTATION Proprietary, High-Value Technology Critical supplier status with leading companies: Regenerative medicine Cord blood banks Suppliers of cells used in drug screening

Revenue Model Key to Record Growth 16 OCTOBER 2011 INVESTOR PRESENTATION * Trailing 12 Months

OCTOBER 2011 INVESTOR PRESENTATION 17 Growth Trends Record Revenue in Last 5 Quarters (000’s)

Investment Summary OCTOBER 2011 INVESTOR PRESENTATION 18 Best-in-class, proprietary, first-choice market position Leading supplier of clinical grade biopreservation media products BioLife technology is embedded in numerous current & development stage clinical products Significant revenue upside upon regulatory approval of customer products High-quality, scalable GMP manufacturing facility ISO 13485 certified FDA Master Files Annual revenue growth of 30% - 50% Moving to the NASDAQ exchange

OTCBB: BLFS http://biolifesolutions.com